Our company news

We are working on the following new projects: • We signed 2 contracts for bioequivalence trials with Rivaraxoban.

His report thus illustrates his awareness of the need to guard against selection bias and shows how he attempted to hold constant potential confounding factors - clinical condition, environment, and basic diet

April We are working on the following new projects: • We have been awarded several bioequivalence studies

We were awarded with several bioequivalence trials for full services activities (Umifenovir, Tadalafil, Ipidacrine, Sertraline, Silodosine).

Smooth together with Chinese colleagues hosts a seminar on European Pharma & Medical Device Regulation and Overseas Clinical Trial Strategies on 3 April. Feel free to join.

We were awarded with projects for development of medical documentation and data management.

Compliance with standards is a necessary part of doing business to operate, especially in the field of clinical trials, where the welfare of subjects comes first.

We are working on the following new projects: • We signed several contracts for medical wring activities for BE trials with different clients.

Smooth Drug Development achievements in China Smooth Drug Development opened a representative office in China and plans to continue its contribution to the development of therapeutics in China and assist Chinese clients enter EAEU and EC markets

We are working on the following new projects: • We were awarded with a bioequivalence trial of Ketorolac.

We are working on the following new projects: • We signed the contract for the trial of III phase in inflammatory and degenerative diseases of the musculoskeletal system.

We are working on the following new projects: We signed the contracts for the III phase Nimesulide trials of in dorsopathy and postoperative pain.

We are working on the following new projects: • We signed a contract for medical writing activities with Fabomotizole.

We are working on the following new projects: • We were awarded with two contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.